Related Experiment Video
Updated: Feb 28, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
8.0K
Revisiting the OGIPRO Trial: Dynamic Electronic Patient-Reported Outcomes Compared with EQ-5D-5L in HER2-Positive
Anatol Aicher1, Marcus Vetter2,3, David Blum1,4
1Medical Faculty, University of Zurich, 8006 Zurich, Switzerland.
Cancers
|February 27, 2026
Summary
Dynamic electronic patient-reported outcomes (ePROs) for well-being closely align with the EQ-5D-5L visual analogue scale, validating their use in oncology. However, ePRO symptom data showed weaker agreement with EQ-5D-5L domains, requiring further research.
Area of Science:
- Oncology
- Digital Health
- Health Economics
Background:
- Patient-reported outcomes (PROs) are crucial for assessing cancer treatment tolerability and quality of life.
- Dynamic electronic PROs (ePROs) offer high-frequency longitudinal data, but their alignment with established measures like EQ-5D-5L is unclear.
- This study investigates the concordance between ePRO data and EQ-5D-5L in HER2-positive breast cancer patients.
Purpose of the Study:
- To evaluate the alignment between dynamic ePRO well-being scores and the EQ-5D-5L visual analogue scale (VAS).
- To assess the agreement between aggregated ePRO symptom grades and EQ-5D-5L domain scores and disutility.
- To determine the utility of ePROs as a substitute for EQ-5D-5L in clinical and research settings.
Main Methods:
- Retrospective analysis of data from the prospective OGIPRO trial (KEK-ZH 2021-D0051).
- Utilized linear mixed-effects modeling to analyze 13,699 dynamic ePRO data points from 53 patients with HER2-positive breast cancer.
- Compared ePRO well-being with EQ-5D-5L VAS, and ePRO symptom grades with EQ-5D-5L domain sums and disutility.
Main Results:
- Dynamic ePRO well-being demonstrated strong agreement with EQ-5D-5L VAS (β = 1.061), indicating low between-patient variability.
- Agreement between aggregated ePRO symptom grades and EQ-5D-5L domains/disutility was weaker and more heterogeneous across patients (β = 0.404 and β = 0.213, respectively).
Conclusions:
- Dynamic ePRO well-being is a valid substitute for EQ-5D-5L VAS in oncology research and clinical practice.
- Aggregated ePRO symptom data show limited concordance with EQ-5D-5L domains, suggesting a need for more granular analysis and larger datasets.
- Dynamic ePRO systems offer a scalable foundation for patient monitoring and AI-driven decision support in precision oncology.
Related Concept Videos
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
192
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192
01:11Guidelines for Writing Outcome
4.2K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
4.2K
01:21Cancer Survival Analysis
805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805
01:16Bioequivalence: Overview
2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K